Neurogene Inc. (NGNE): Nasdaq/NYSE listing notice — Neoleukin receives Nasdaq delisting notice for bid price below $1.00

Neurogene Inc.

Nasdaq notice on Oct 26, 2022 for non-compliance with minimum bid price rule (5550(a)(2)).
Initial 180-day cure period ends April 24, 2023; needs $1.00+ close for 10 consecutive days.
May seek transfer to Nasdaq Capital Market for second 180-day grace period if eligible.
Company evaluating actions but no decisions made; delisting risk remains if not cured.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Neurogene Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

October 26, 2022, Neoleukin Therapeutics, Inc. (the “Company”) received notice (the "Notice") from the Listing Qualifications staff of the Nasdaq Stock Market LLC (“Nasdaq”) that, because the closing bid price for the Company's common stock has fallen below $1.00 per share for 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5550(a)(2). The Notice has no immediate effect on the listing of the Company's common stock on the Nasdaq Global Market. Pursuant to Nasdaq Listin

View on SEC.gov

6 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Neurogene Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-027409

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.